Travere Therapeutics
3611 Valley Centre Drive
Suite 300
San Diego
California
92130
United States
Tel: 888-969-7879
Website: https://travere.com/
About Travere Therapeutics
Are you inspired to make a difference for people living with rare disease? So are we. Our mission is to identify, develop, and deliver life-changing therapies to people living with rare disease. To accomplish this, we need talents like yours. Our exceptional employees are vital to our mission and are our biggest asset.
Many of us are rare disease patients, survivors, and caregivers. For us, advancing research, delivering life-changing therapeutics, and doing everything we can to support the rare disease community is personal. It’s why we are dedicated to the rare disease community and why we’re proud to be in rare for life.
We take our mission seriously. Our responsibility to the communities we serve motivates and inspires us. You can have a meaningful and dynamic career at Travere. From new roles to expanded responsibilities, we empower our employees to take charge of their professional future by providing opportunities that align with each employee’s skill sets and passions.
Travere employees work cross-functionally, collaborating with colleagues throughout the organization, and serve on committees such as our internal diversity council. At Travere, your voice is heard and valued. Every employee is integral to our success – we are stronger together.
We’re looking to hire people who are inspired by our mission and our purpose and bring diverse perspectives to our business. Don’t see a position in your field of expertise? Join the Travere Talent Community to stay connected.
Community members can:
- Receive alerts about new career opportunities that match your interests.
- Share job postings with friends and family through social media or email.
- Stay connected with our Talent Acquisition team.
Please note that joining the Travere Talent Community is not an application for any specific job at Travere Therapeutics.
Learn more about our patient-inspired, people-centered company at travere.com/careers.
339 articles about Travere Therapeutics
-
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
11/21/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET.
-
Travere Therapeutics Reports Third Quarter 2023 Financial Results
11/7/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2023 financial results and provided a corporate update.
-
Following two late-stage failures, Travere Therapeutics has unveiled the results of two Phase III studies, attempting to regain Filspari’s footing in IgA nephropathy and focal segmental glomerulosclerosis.
-
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
11/3/2023
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced additional data from two pivotal clinical studies demonstrating sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure compared to an active comparator, suggesting long-term benefits in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
-
Travere Therapeutics to Report Third Quarter 2023 Financial Results
10/24/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the U.S. financial markets.
-
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
10/13/2023
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including two late-breaking oral presentations, at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 2-5, 2023.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 11, 2023
10/11/2023
Travere Therapeutics, Inc. announced that on October 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to nine new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 29,250 shares of its common stock.
-
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
9/26/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential effect of FILSPARI® (sparsentan) as a first-line therapy in patients with newly diagnosed IgA nephropathy (IgAN) in a late-breaking trial session at the 17th International Symposium on IgA Nephropathy (IIGANN2023) in Ryogoku, Tokyo, September 28-30, 2023.
-
ARS Pharmaceuticals, Intarcia Therapeutics and Taysha Gene Therapies this week got stark reminders of the difficulties in getting treatments through the regulator’s approval process.
-
The company’s treatment for IgA nephropathy, sparsentan, failed to meet statistical significance by a measure of kidney function in a head-to-head confirmatory study versus irbesartan.
-
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
9/21/2023
Travere Therapeutics, Inc. announced topline two-year confirmatory secondary endpoint results from the Company’s pivotal head-to-head Phase 3 PROTECT Study of FILSPARI® in IgA nephropathy versus irbesartan.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 11, 2023
9/11/2023
Travere Therapeutics, Inc. announced that on September 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 8,250 shares of its common stock.
-
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
9/5/2023
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”).
-
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
9/5/2023
Travere Therapeutics, Inc. and Mirum Pharmaceuticals, Inc. announced the completion of the previously announced sale of Travere’s bile acid product portfolio that includes Cholbam® and Chenodal®, two medications addressing rare diseases in high-need settings.
-
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
8/31/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023, at 10:15 a.m. ET.
-
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
8/24/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Jerusalem, Israel, August 29 – September 1, 2023.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 14, 2023
8/14/2023
Travere Therapeutics, Inc. announced that on August 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to nine new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 34,100 shares of its common stock.
-
Travere Therapeutics Reports Second Quarter 2023 Financial Results
8/3/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2023 financial results and provided a corporate update.
-
Travere Therapeutics to Report Second Quarter 2023 Financial Results
7/20/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets.
-
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
7/17/2023
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that they have entered into a definitive agreement for the sale of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings.